These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

218 related items for PubMed ID: 21796376

  • 1. Optimal dose finding of garenoxacin based on population pharmacokinetics/pharmacodynamics and Monte Carlo simulation.
    Tanigawara Y, Nozawa K, Tsuda H.
    Eur J Clin Pharmacol; 2012 Jan; 68(1):39-53. PubMed ID: 21796376
    [Abstract] [Full Text] [Related]

  • 2. Population pharmacokinetics and pharmacodynamics of garenoxacin in patients with community-acquired respiratory tract infections.
    Van Wart S, Phillips L, Ludwig EA, Russo R, Gajjar DA, Bello A, Ambrose PG, Costanzo C, Grasela TH, Echols R, Grasela DM.
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4766-77. PubMed ID: 15561855
    [Abstract] [Full Text] [Related]

  • 3. Population pharmacokinetics and pharmacodynamics of sitafloxacin in patients with community-acquired respiratory tract infections.
    Tanigawara Y, Kaku M, Totsuka K, Tsuge H, Saito A.
    J Infect Chemother; 2013 Oct; 19(5):858-66. PubMed ID: 23529500
    [Abstract] [Full Text] [Related]

  • 4. Pharmacodynamics of the new des-f(6)-quinolone garenoxacin in a murine thigh infection model.
    Andes D, Craig WA.
    Antimicrob Agents Chemother; 2003 Dec; 47(12):3935-41. PubMed ID: 14638504
    [Abstract] [Full Text] [Related]

  • 5. Proposed Pharmacokinetic-Pharmacodynamic Breakpoint of Garenoxacin and Other Quinolones.
    Yamagishi Y, Shibata T, Nakagawa S, Nomura N, Mitsuyama J, Mikamo H.
    Jpn J Infect Dis; 2017 Nov 22; 70(6):616-620. PubMed ID: 28890509
    [Abstract] [Full Text] [Related]

  • 6. [Prediction on the efficacy of fluoroquinolones for anaerobic infections using Monte Carlo simulation].
    Mikamo H, Tanaka K, Watanabe K.
    Jpn J Antibiot; 2007 Dec 22; 60(6):335-43. PubMed ID: 18447205
    [Abstract] [Full Text] [Related]

  • 7. Comparative pharmacodynamics of garenoxacin, gemifloxacin, and moxifloxacin in community-acquired pneumonia caused by Streptococcus pneumoniae: a Monte Carlo simulation analysis.
    Noreddin AM, Reese AA, Ostroski M, Hoban DJ, Zhanel GG.
    Clin Ther; 2007 Dec 22; 29(12):2685-9. PubMed ID: 18201584
    [Abstract] [Full Text] [Related]

  • 8. Population pharmacokinetics and target attainment analysis of moxifloxacin in patients with diabetic foot infections.
    Wicha SG, Haak T, Zink K, Kees F, Kloft C, Kees MG.
    J Clin Pharmacol; 2015 Jun 22; 55(6):639-46. PubMed ID: 25600294
    [Abstract] [Full Text] [Related]

  • 9. Gemifloxacin for the treatment of respiratory tract infections: in vitro susceptibility, pharmacokinetics and pharmacodynamics, clinical efficacy, and safety.
    Bhavnani SM, Andes DR.
    Pharmacotherapy; 2005 May 22; 25(5):717-40. PubMed ID: 15899734
    [Abstract] [Full Text] [Related]

  • 10. Pharmacokinetic evaluation of marbofloxacin after intravenous administration at different ages in llama crias, and pharmacokinetic/pharmacodynamic analysis by Monte Carlo simulation.
    Rubio-Langre S, Aguilar-Sola S, Lorenzutti AM, San Andrés MI, De Lucas JJ, Litterio NJ.
    J Vet Pharmacol Ther; 2018 Dec 22; 41(6):861-870. PubMed ID: 30020535
    [Abstract] [Full Text] [Related]

  • 11. Population Pharmacokinetic Modeling Using Polymyxin B Free Plasma Concentrations From Published Reports and Evaluation of Dosage Regimens Based on Monte Carlo Simulation in Critically Ill Patients.
    Zheng Y, Xu B, Chen S, Liu M, Huang H, Wang J, Wu X.
    J Clin Pharmacol; 2023 Sep 22; 63(9):1036-1044. PubMed ID: 37125471
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetics of garenoxacin in elderly patients with respiratory tract infections.
    Ohsaki Y, Morita K, Takeda H, Kishino S, Okumura S, Fujiuchi S.
    Int J Antimicrob Agents; 2010 Jun 22; 35(6):603-5. PubMed ID: 20207522
    [Abstract] [Full Text] [Related]

  • 13. Clinical studies of garenoxacin.
    Takagi H, Tanaka K, Tsuda H, Kobayashi H.
    Int J Antimicrob Agents; 2008 Dec 22; 32(6):468-74. PubMed ID: 18790608
    [Abstract] [Full Text] [Related]

  • 14. Determining optimal dosing regimen of oral administration of dicloxacillin using Monte Carlo simulation.
    Yu W, Ji J, Xiao T, Ying C, Fang J, Shen P, Xiao Y.
    Drug Des Devel Ther; 2017 Dec 22; 11():1951-1956. PubMed ID: 28721014
    [Abstract] [Full Text] [Related]

  • 15. Pharmacodynamic analysis of ceftriaxone, gatifloxacin,and levofloxacin against Streptococcus pneumoniae with the use of Monte Carlo simulation.
    Frei CR, Burgess DS.
    Pharmacotherapy; 2005 Sep 22; 25(9):1161-7. PubMed ID: 16164390
    [Abstract] [Full Text] [Related]

  • 16. Physiologically Based Pharmacokinetic Model for Predicting Omadacycline Pharmacokinetics and Pharmacodynamics in Healthy and Hepatic Impairment Populations.
    Zhang A, Sun Y, Zuo M, Wei H, Chen J, Zhao M, Yang W, Zhu L.
    Clin Ther; 2024 Aug 22; 46(8):629-635. PubMed ID: 39069431
    [Abstract] [Full Text] [Related]

  • 17. [Antibacterial activity of quinolones against various clinically isolated strains and evaluation of efficacy based on the pharmacokinetics/pharmacodynamics theory].
    Nakamura T, Shimizu C, Hirakawa K, Inui S, Okuda K, Nakata C, Fujimoto H, Okura H, Uemura Y, Takahashi H.
    Jpn J Antibiot; 2009 Jun 22; 62(3):194-202. PubMed ID: 19882980
    [Abstract] [Full Text] [Related]

  • 18. Optimal dosing regimen of biapenem in Chinese patients with lower respiratory tract infections based on population pharmacokinetic/pharmacodynamic modelling and Monte Carlo simulation.
    Dong J, Xiong W, Chen Y, Zhao Y, Lu Y, Zhao D, Li W, Liu Y, Chen X.
    Int J Antimicrob Agents; 2016 Mar 22; 47(3):202-9. PubMed ID: 26895604
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetic/pharmacodynamic evaluation of marbofloxacin as a single injection for Pasteurellaceae respiratory infections in cattle using population pharmacokinetics and Monte Carlo simulations.
    Paulin A, Schneider M, Dron F, Woehrle F.
    J Vet Pharmacol Ther; 2018 Feb 22; 41(1):39-50. PubMed ID: 28542866
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.